Pune, India -- (SBWIRE) -- 10/30/2020 -- Biliary Tumor Drug Development Pipeline Analysis 2020 is latest report on Global Biliary Tumor Drug Pipeline published By Fortune Business Insights. The rising prevalence of biliary tumor and increased research spending have encouraged many pharmaceutical companies to develop a novel therapy for the treatment of the biliary tumor. For instance; DKN-01, a humanized monoclonal antibody is being developed by Leap Therapeutics, Inc. is currently under phase 1 clinical trials for the treatment of bile duct cancer through is anti-neoplastic activity.

Biliary Tumor is a type of cancer which develops in the area that connects the gall bladder, small intestine, and liver, commonly called a bile duct. It can be classified into three types namely intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, and distal cholangiocarcinoma. The common symptoms of biliary tumor include abdominal pain, weight loss, fatigue, white-colored stools, itchy skin, and others.

Get Sample Biliary Tumor Drug Development Pipeline Analysis 2020 Report

According to the America Cancer Society, bile duct cancer is more common in Southeast Asia. In the U.S. approximately 8,000 people are diagnosed with bile duct cancer each year. The current treatment for biliary treatment includes radiation therapy, chemotherapy, and surgery. The drugs often prescribed for biliary cancer are gemcitabine, oxaliplatin, 5-fluorouracil, cisplatin, and others.

The report on 'Biliary Tumor– Pipeline Review, 2019' provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Biliary Tumor. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Biliary Tumor.

The report on 'Biliary Tumor – Pipeline Review, 2019', which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

REPORT SCOPE

Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
Overview of dormant and discontinued pipeline products
Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
Overview of the latest developments; news articles, press releases and relevant conferences
REPORT METHODOLOGY

All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases
REASONS TO BUY THIS REPORT

Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Biliary Tumor
Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
Identify the focus of leading players in relation to R&D for Biliary Tumor
Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary
TABLE OF CONTENT:

1. Introduction

1.1. Report Overview

2. Biliary Tumor- Overview

3. Executive Summary

4. Biliary Tumor: Pipeline Assessment

4.1. By Stage of Development

4.2. By Route of Administration

4.3. By Drug Class

4.4. By Molecule Type

4.5. By Therapy Area / Indication

4.6. By Drug Target

4.7. By Sponsor

5. Biliary Tumor: Company &Drug Profiles

5.1. Clinical Stage

5.1.1. Surufatinib – HutchisonMedipharma Limited

5.1.1.1. Company Overview

5.1.1.2. Product Description

5.1.1.3. R&D Status &Development Activities

5.1.1.4. Mechanism of Action

5.1.1.5. Molecule Type

5.1.1.6. Stage of Development

5.1.1.7. Indications

5.1.1.8. Route of Administration

5.1.1.9. Funding

5.1.2. Varlitinib – Aslan Pharmaceuticals

5.1.2.1. Company Overview

5.1.2.2. Product Description

5.1.2.3. R&D Status &Development Activities

5.1.2.4. Mechanism of Action

5.1.2.5. Molecule Type

5.1.2.6. Stage of Development

5.1.2.7. Indications

5.1.2.8. Route of Administration

5.1.2.9. Funding

5.1.3. DKN-01 – Leap Therapeutics, Inc.

5.1.3.1. Company Overview

5.1.3.2. Product Description

5.1.3.3. R&D Status &Development Activities

5.1.3.4. Mechanism of Action

5.1.3.5. Molecule Type

5.1.3.6. Stage of Development

5.1.3.7. Indications

5.1.3.8. Route of Administration

5.1.3.9. Funding

5.1.4. Others

5.2. Preclinical

5.2.1. Company Overview

5.2.2. Product Description

5.2.3. R&D Status &Development Activities

5.2.4. Mechanism of Action

5.2.5. Molecule Type

5.2.6. Indications

5.2.7. Route of Administration

5.2.8. Funding

6. Biliary Tumor: An Overview on Dormant & Discontinued Pipeline Candidates

6.1. Overview

6.2. Product Description

6.3. Reason for Discontinuation

7. Biliary Tumor: Additional Key Insights

7.1. Epidemiology Overview: Biliary Tumor

7.2. Current Market Scenario: Biliary Tumor Therapeutics

7.3. Overview of Government Funded Biliary Tumor Research Grants Programs

7.4. Overview of Approved Drugs for Bile Duct Cancer

8. Biliary Tumor: News, Press Releases and Conference Details

About Fortune Business Insights
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune -411045, Maharashtra, India.

US: +1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245